Medical Sector Earnings Show Promise Despite Some Concerns

The earnings cycle for the medical sector is ongoing, showing strong performances from major players like J&J and AbbVie. Investor attention is drawn to the positive earnings projections amid some caution about sales guidance for 2025.

Date: 04-02-2025

AI Rating: 7

Earnings Per Share (EPS)
Amgen has an EPS estimate of $5.03 for the fourth quarter, indicating positive expectations. CRISPR Therapeutics anticipates a loss per share of $1.17, while Moderna expects a loss of $2.86. Sarepta and Vertex have EPS estimates of $1.69 and $4.00, respectively.

Revenue Growth
The overall fourth-quarter earnings and sales for the medical sector are projected to see increases of 12.5% and 8.6% year over year. Additionally, Amgen has achieved an average earnings surprise of 4.10% over the trailing four quarters.

Profit Margins
While not explicitly detailed, the positive earnings beat percentage for pharma companies reveals potentially healthy profit margins.

Overall, the report indicates a positive outlook for the medical sector with strong earnings performance, despite some individual company projections presenting challenges. The report highlights the importance of guidance and the mixed results in revenue performances that investors should consider. With the overall earnings and revenue trends indicating growth, the sector appears to be in a good position, but caution around specific guidance could influence stock price movements.

Stocks: AMGN CRSP MRNA SRPT VRTX